ArticleFrontiers in oncology2025
Clinical outcomes of combination therapy for hepatocellular carcinoma in a predominantly hispanic South Texas population.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Currently, studies looking at hepatocellular carcinoma treatments with combination immunotherapy and locoregional therapies are limited in scope. Our study aimed to further clarify the impact of combination therapy using immunotherapy and locoregional therapy on mortality in patients with hepatocellular carcinoma. Methods: A chart review was conducted on patients with hepatocellular carcinoma who had received either immunotherapy or tyrosine kinase inhibitors. Patients were classified into four treatment arms: 1. Patients treated with locoregional therapy and immunotherapy. 2. Patients treated with locoregional therapy and tyrosine kinase inhibitors. 3. Patients treated with immunotherapy but without locoregional therapy. 4. Combination treatment arm containing Arms 1 and 2. The primary objective was overall survival immunotherapy alone versus combination treatments. Results: A total of 135 patient charts were analyzed in this study. One hundred nine patients had received immunotherapy, and 102 had received locoregional therapy. Cumulative median survival for all patients from the date of diagnosis was 1.55 years. Median survival for the immunotherapy arm was 0.51 years, and median survival for the combination treatment arm was 2.25 years. Results from the Cox proportional hazards regression model comparing the combination treatment groups against the immunotherapy arm found a hazard ratio of 0.21 (0.12-0.39; p<0.05). Conclusion: In this study of hepatocellular carcinoma, combination treatment groups receiving locoregional therapy with either tyrosine kinase inhibitors or immunotherapy demonstrated improved survival compared to immunotherapy alone. These results highlight the importance of tailored treatment strategies, particularly in patients with preserved liver function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.